Helen Won
Eli Lilly (United States)(US)Sungkyunkwan University(KR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, Advanced Breast Cancer Therapies, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients(2017)3,455 cited
- → Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)(2015)2,114 cited
- → ESR1 ligand-binding domain mutations in hormone-resistant breast cancer(2013)1,235 cited
- → HER kinase inhibition in patients with HER2- and HER3-mutant cancers(2018)769 cited
- → Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor(2014)575 cited
- → Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial(2018)552 cited
- → A rectal cancer organoid platform to study individual responses to chemoradiation(2019)550 cited
- → High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden(2019)489 cited
- → Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor(2016)473 cited
- → Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets(2016)463 cited